Rabeprazole Sodium Tablet, Delayed Release
Product Images NDC 72162-2503

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rabeprazole Sodium (NDC 72162-2503). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721622503)

Label for Rabeprazole Sodium delayed-release tablets, 20 mg, containing 30 tablets per bottle. The label includes the NDC 72162-2503-3 and notes the product is Rx only. It is relabeled by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by Rubicon Research Private Limited. Storage instructions and pharmacist dispensing guidelines are also included.*

FDA Label Image

Structural Image (Rabeprazole Dr Tablet 01)

Chemical structure diagram of rabeprazole sodium, illustrating the molecular arrangement and bonding of the active ingredient.*

FDA Label Image

Figure 2: Mean Daytime Heartburn Scores Rab-usa-2 (Rabeprazole Dr Tablet 02)

A line graph displaying mean heartburn scores over a study period for placebo, rabeprazole 10 mg, and rabeprazole 20 mg groups. The x-axis shows study days ranging from -14 to 28, and the y-axis shows heartburn scores from 0 to 4, indicating severity. Scores decrease after day 0, with separate lines for each treatment group.*

FDA Label Image

Figure 3: Mean Nighttime Heartburn Scores Rab-usa-2 (Rabeprazole Dr Tablet 03)

A line graph comparing mean heartburn scores over a study period for three groups: placebo, RAB 10 mg, and RAB 20 mg. The x-axis represents study days from -14 to 28, and the y-axis shows mean heartburn scores, ranging from 0 (none) to 4 (very severe). The graph shows a decrease in heartburn scores after day 0 for active treatment groups compared to placebo.*

FDA Label Image

Figure 4: Mean Daytime Heartburn Scores Rab-usa-3 (Rabeprazole Dr Tablet 04)

A line graph comparing mean heartburn scores over study days for two groups: placebo (n=58) and rabeprazole sodium 20 mg (n=59). The horizontal axis represents study days from -14 to 28, while the vertical axis shows mean heartburn scores ranging from 0 (None) to 4 (Very Severe). The graph illustrates a decrease in heartburn scores after the study start, with the rabeprazole 20 mg group showing a more pronounced reduction than the placebo group.*

FDA Label Image

Figure 5: Mean Nighttime Heartburn Scores Rab-usa-3 (Rabeprazole Dr Tablet 05)

A line graph comparing mean heartburn scores over a 28-day study period between two groups: placebo (n=58) and rabeprazole sodium 20 mg (n=59). The vertical axis represents heartburn scores from 0 (none) to 4 (very severe), and the horizontal axis shows study days before and after treatment start (day 0).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.